-+ 0.00%
-+ 0.00%
-+ 0.00%

Valneva Announces U.K.'s Commission On Human Medicines Restricts People Aged 60+ From Using IXCHIQ Chikungunya Vaccine

Benzinga·02/13/2026 16:48:39
Listen to the news

Valneva SE  (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's single‑dose chikungunya vaccine, IXCHIQ®, the United Kingdom's (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine.

The updated Prescribing Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for people with specified health conditions, as well as timing of vaccination prior to travel. For further details please refer to this Link.

The MHRA confirmed that the benefit–risk profile of IXCHIQ® remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection and do not have the contraindicated underlying medical conditions.